Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429177 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL18415154 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL13131231 | 1.00 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL17771882 | 0.98 | KEAP1 (0.58) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL10306736 | 0.89 | CYP2D6 (0.48) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL18911003 | 0.84 | NPC1 (0.42) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL19130799 | 0.84 | NPC1 (0.42) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL21141108 | 0.82 | KEAP1 (0.51) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL20732594 | 0.82 | KEAP1 (0.51) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL18905366 | 0.82 | KEAP1 (0.40) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113552235-A | Method for measuring content of 1-cyclohexyl-1-phenethyl alcohol impurity in trihexyphenidyl hydrochloride by gas chromatography | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | claimed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| CN-113552235-A | Method for measuring content of 1-cyclohexyl-1-phenethyl alcohol impurity in trihexyphenidyl hydrochloride by gas chromatography | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3895705-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | University of Manitoba (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2020244452-A1 | HETEROCYCLIC DERIVATIVE HAVING β2 RECEPTOR AGITATION AND M RECEPTOR ANTAGONISTIC ACTIVITY AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| WO-2017012489-A1 | BENZO RING DERIVATIVE WITH Β2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2017-01-26 | — | — | WO | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8624024-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY OF MANITOBA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2128167-A1 | PHOSPHOROAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | National University Corporation Nagoya University (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | KEAP1 79/4885NFE2L2 494/4885CHRM2 4729/4885 |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | HCAR2, CHRM3, BDKRB2 | KEAP1 3592/4885NFE2L2 2057/4885CHRM2 4/4885 |
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | CHRNA5, CHRM2, GAP43 | KEAP1 3131/4885NFE2L2 4545/4885CHRM2 2/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | KEAP1 147/4885NFE2L2 1349/4885CHRM2 4098/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | KEAP1 79/4885NFE2L2 494/4885CHRM2 4729/4885 |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | KEAP1 2748/4885NFE2L2 1705/4885CHRM2 2966/4885 |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | KEAP1 2748/4885NFE2L2 1705/4885CHRM2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.